<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462187</url>
  </required_header>
  <id_info>
    <org_study_id>NI-WA201</org_study_id>
    <nct_id>NCT02462187</nct_id>
  </id_info>
  <brief_title>Topical NVN1000 for the Treatment of External Genital and Perianal Warts</brief_title>
  <official_title>A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled, ascending dose study to assess
      safety, tolerability and efficacy of a topical nitric oxide releasing compound in subjects
      with external genital and perianal warts. Eligible subjects will be treated with a topical
      gel (active or vehicle) for up to 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2015</start_date>
  <completion_date type="Actual">October 17, 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Clearance of baseline external genital and perianal warts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clearance of baseline external genital and perianal warts as determined by physical examination by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Topical NVN1000 Gel as determined by Scores on a 4 point grading scale for erythema, edema, erosions/ulcers, and itch</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of scores for erythema, edema, erosions/ulcers, itch between active and vehicle treated subjects using a 4 point grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by reported adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of reported adverse events in active and vehicle treated subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by changes in laboratory assessments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of changes in laboratory assessments between active and vehicle treated subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete clearance of all warts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clearance of baseline and warts that emerge during treatment period as determined by physical examination by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete or partial clearance of baseline warts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in the number of baseline warts as determined by physical examination by the investigator</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Genital Warts</condition>
  <condition>Perianal Warts</condition>
  <arm_group>
    <arm_group_label>NVN1000 8% Gel twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVN1000 8% Gel twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVN1000 8% Gel once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVN1000 8% Gel once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVN1000 16% Once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVN1000 16% Gel once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Gel at frequency to match active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVN1000 24% once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVN1000 24% once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVN1000</intervention_name>
    <description>Applied topically, co-administered with hydrogel</description>
    <arm_group_label>NVN1000 8% Gel twice daily</arm_group_label>
    <arm_group_label>NVN1000 8% Gel once daily</arm_group_label>
    <arm_group_label>NVN1000 16% Once daily</arm_group_label>
    <arm_group_label>NVN1000 24% once daily</arm_group_label>
    <other_name>SB206</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Applied topically, co-administered with hydrogel</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 2 but not more than 20 genital/perianal warts with a maximum total wart
             surface area no more than 1% body surface area

          -  If a woman of child-bearing potential, have a negative pregnancy test and use
             effective contraception

          -  If currently receiving wart treatment, be willing to stop all treatment for 28 days
             prior to randomization and during the study

        Exclusion Criteria:

          -  Immunocompromised patients including those with HIV, receiving radiation, or drugs
             that suppress the immune system

          -  Pregnant, planning to become pregnant, or nursing

          -  History of cancer (including cervical cancer) within 5 years, with exception of
             non-melanoma skin cancer in non-genital skin

          -  Recent history of other genital skin infections

          -  Active HSV and frequent HSV recurrences unless receiving suppression therapy

          -  Have hemoglobin &lt; 10 G/dl or methemoglobin &gt; 3%

          -  Known allergy to any component of the gel including excipients

          -  Previously participated in any study with NVN1000 or SB204
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce Rico, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD 137</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 140</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 133</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 134</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 139</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 138</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 130</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 126</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 132</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 135</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 128</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 129</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 127</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 131</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>75598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD 136</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <disposition_first_submitted>December 21, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 21, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 27, 2017</disposition_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genital warts</keyword>
  <keyword>perianal warts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

